Clinical efficacy of the novel thiazolidinedione lobeglitazone in patients with type 2 diabetes

被引：7
|
作者：
Lee, J. -Y. [1 ,2 ]
Cho, Y. [1 ,2 ]
Lee, M. [1 ,2 ]
Lee, Y. -H. [1 ,2 ,3 ]
Lee, B. -W. [1 ,2 ,3 ]
Kang, E. S. [1 ,2 ,3 ]
Cha, B. -S. [1 ,2 ,3 ]
机构：
[1] Yonsei Univ, Dept Internal Med, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Grad Sch, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Inst Endocrine Res, Coll Med, Seoul, South Korea
来源：
DIABETES & METABOLISM | 2018年 / 44卷 / 05期
关键词：
INSULIN-RESISTANCE; DOUBLE-BLIND; PIOGLITAZONE; TOLERABILITY; METFORMIN; THERAPY; VILDAGLIPTIN; MONOTHERAPY; 24-WEEK;
D O I：
10.1016/j.diabet.2017.11.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：452 / 455
页数：4
相关论文
共 50 条
  • [11] A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
    Kim, Bo-Yeon
    Kwon, Hyuk-Sang
    Kim, Suk Kyeong
    Noh, Jung-Hyun
    Park, Cheol-Young
    Park, Hyeong-Kyu
    Song, Kee-Ho
    Won, Jong Chul
    Yu, Jae Myung
    Lee, Mi Young
    Lee, Jae Hyuk
    Lim, Soo
    Chun, Sung Wan
    Jeong, In-Kyung
    Chung, Choon Hee
    Han, Seung Jin
    Kim, Hee-Seok
    Min, Ju-Young
    Kim, Sungrae
    DIABETES & METABOLISM JOURNAL, 2022, 46 (06) : 855 - 865
  • [12] Thiazolidinedione derivatives in type 2 diabetes mellitus
    Tack, C. J. J.
    Smits, P.
    NETHERLANDS JOURNAL OF MEDICINE, 2006, 64 (06) : 166 - 174
  • [13] Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
    Yoo, Joonsang
    Jeon, Jimin
    Baik, Minyoul
    Kim, Jinkwon
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [14] Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure
    Seong, Jong-Mi
    Choi, Nam-Kyong
    Jung, Sun-Young
    Chang, Yoosoo
    Kim, Ye-Jee
    Lee, Joongyub
    Park, Byung-Joo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (04) : 344 - 350
  • [15] Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes
    Chang, Tien-Jyun
    Liu, Pi-Hua
    Liang, Yi-Chi
    Chang, Yi-Cheng
    Jiang, Yi-Der
    Li, Hung-Yuan
    Lo, Min-Tzu
    Chen, Harn-Shen
    Chuang, Lee-Ming
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (12) : 829 - 836
  • [16] Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
    Hollander, Priscilla L.
    Li, Jia
    Frederich, Robert
    Allen, Elsie
    Chen, Roland
    DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (02) : 125 - 135
  • [17] Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis
    Lin, Chu
    Li, Zong-Lin
    Cai, Xiao-Ling
    Hu, Sui-Yuan
    Lv, Fang
    Yang, Wen-Jia
    Ji, Li-Nong
    WORLD JOURNAL OF DIABETES, 2023, 14 (10) : 1573 - 1584
  • [18] Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes
    Cho, Yun Kyung
    Lee, Jiwoo
    Kang, Yu Mi
    Yoo, Jee Hee
    Park, Joong-Yeol
    Jung, Chang Hee
    Lee, Woo Je
    PLOS ONE, 2019, 14 (08):
  • [19] Thiazolidinedione use and risk of Parkinson's disease in patients with type 2 diabetes mellitus
    Zhao, Houyu
    Zhuo, Lin
    Sun, Yexiang
    Shen, Peng
    Lin, Hongbo
    Zhan, Siyan
    NPJ PARKINSONS DISEASE, 2022, 8 (01)
  • [20] The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
    Cai, L.
    Cai, Y.
    Lu, Z. J.
    Zhang, Y.
    Liu, P.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (04) : 386 - 398
12345